Study reveals the roles of a nucleic acid sensor for COVID-19 in pan-cancer

Toll-like receptor 7 (TLR7), a severe acute respiratory syndrome 2 (SARS-CoV-2) virus's nucleic acid sensor, was discovered to be aberrantly expressed in many types of cancers. However, its expression pattern across cancers and association with COVID-19 (or its causing virus SARS-CoV-2) has not been systematically studied.

Coronavirus disease 2019 (COVID-19) was a disease mainly characterized by damage to the respiratory system caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recent studies suggest that cancer was a risk factor for coronavirus disease 2019 (COVID-19).

In this study, the authors of this article propose a computational framework to comprehensively study the roles of TLR7 in COVID-19 and pan-cancers at genetic, gene expression, protein, epigenetic, and single-cell levels. As a result, TLR7 expression was found to be higher in the lung of mice infected with SARS-CoV-2 than that in the control group.

This study reveals the roles of TLR7, a nucleic acid sensor for COVID-19 in pan-cancer. These findings might be necessary for preventing SARS-CoV-2 infection and alleviating cytokine storms in infected cancer patients.

Source:
Journal reference:

Zhijian Huang, Yaoxin Gao, Yuanyuan Han, Jingwen Yang, Can Yang, Shixiong Li, Decong Zhou, Qiuyan Huang, Jialiang Yang, Revealing the roles of TLR7, a nucleic acid sensor for COVID-19 in pan-cancer, Biosafety and Health, 2023, https://doi.org/10.1016/j.bsheal.2023.05.004.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Australian research unlocks new path for cancer immunotherapy